|
Huntington Disease
|
0.060 |
Biomarker
|
disease |
BEFREE |
Diagnosis of Huntington's disease via sequential 18F-DOPA and 18F-FDG PET/MRI.
|
31344728 |
2019 |
|
Dermatomyositis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
• [18F]-FDG PET-scanner standardised uptake value (SUV) could reflect disease activity in dermatomyositis (DM).
|
31250167 |
2019 |
|
Adult type dermatomyositis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
• [18F]-FDG PET-scanner standardised uptake value (SUV) could reflect disease activity in dermatomyositis (DM).
|
31250167 |
2019 |
|
Osteosarcoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
• The baseline <sup>18</sup> F-FDG PET tumor texture features can predict tumor NAC response for patients with osteosarcoma.
|
30859285 |
2019 |
|
Osteosarcoma of bone
|
0.050 |
Biomarker
|
disease |
BEFREE |
• The baseline <sup>18</sup> F-FDG PET tumor texture features can predict tumor NAC response for patients with osteosarcoma.
|
30859285 |
2019 |
|
Childhood Osteosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
• The baseline <sup>18</sup> F-FDG PET tumor texture features can predict tumor NAC response for patients with osteosarcoma.
|
30859285 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
• The baseline <sup>18</sup> F-FDG PET tumor texture features can predict tumor NAC response for patients with osteosarcoma.
|
30859285 |
2019 |
|
Carcinoma of bladder
|
0.080 |
Biomarker
|
disease |
BEFREE |
• Combining metabolical and morphological features using<sup>18</sup>F-FDG PET/CT improves the detection of malignant lymph node in patients with bladder cancer.
|
30666449 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.050 |
Biomarker
|
disease |
BEFREE |
• Combining metabolical and morphological features using<sup>18</sup>F-FDG PET/CT improves the detection of malignant lymph node in patients with bladder cancer.
|
30666449 |
2019 |
|
Bladder Neoplasm
|
0.050 |
Biomarker
|
disease |
BEFREE |
• Combining metabolical and morphological features using<sup>18</sup>F-FDG PET/CT improves the detection of malignant lymph node in patients with bladder cancer.
|
30666449 |
2019 |
|
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
• Bone marrow FDG uptake can provide information on predicting lung cancer progression.
|
27590191 |
2017 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
• Bone marrow FDG uptake can provide information on predicting lung cancer progression.
|
27590191 |
2017 |
|
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
• Bone marrow FDG uptake can provide information on predicting lung cancer progression.
|
27590191 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
• FDG-PET/DWIMRI yields excellent results for the detection of post-radio(chemo)therapy HNSCC recurrence.
|
28812148 |
2018 |
|
Carcinoma of urinary bladder, invasive
|
0.020 |
Biomarker
|
disease |
BEFREE |
• <sup>18</sup> F-FDG PET/CT may help for initial staging of patients with muscle invasive bladder cancer.
|
30666449 |
2019 |
|
Dementia
|
0.100 |
Biomarker
|
disease |
BEFREE |
[F]FDG PET may be useful as a non-invasive diagnostic modality in differentiating the two posterior cortical dementias, despite significant overlap.
|
31633646 |
2019 |
|
Endometrial Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (<sup>18</sup>F-FDG PET CT) has increasing clinical applications supplementing conventional TVUS, CT and MRI imaging in assessing ovarian, cervical and endometrial cancer.
|
28830238 |
2017 |
|
Malignant neoplasm of endometrium
|
0.080 |
Biomarker
|
disease |
BEFREE |
[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (<sup>18</sup>F-FDG PET CT) has increasing clinical applications supplementing conventional TVUS, CT and MRI imaging in assessing ovarian, cervical and endometrial cancer.
|
28830238 |
2017 |
|
Indolent Non-Hodgkin Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
[C]acetate PET/CT exhibited greater sensitivity than [F]FDG PET/CT for lesion detection in patients with less aggressive or indolent lymphomas, thus promising applicability as a physiological tracer in the study of such lesions.
|
30688736 |
2019 |
|
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
[18F]fluorodeoxyglucose positron emission tomography (FDG-PET) showed pronounced relative hypermetabolism of her association cortices and a relative hypometabolism of the primary cortices, on the basis of which an anti-NMDA receptor encephalitis diagnosis was made, and treatment with a steroid pulse was initiated.
|
31749755 |
2019 |
|
Primary Effusion Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
[18F]FDG PET/CT represents a useful tool in the detection of disease response and in the evaluation of outcome in PEL patients.
|
29697219 |
2018 |
|
Pure Erythroid Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
[18F]FDG PET/CT represents a useful tool in the detection of disease response and in the evaluation of outcome in PEL patients.
|
29697219 |
2018 |
|
Vasculitis
|
0.080 |
Biomarker
|
disease |
BEFREE |
[18F]FDG positron emission tomography in patients presenting with suspicion of giant cell arteritis-lessons from a vasculitis clinic.
|
29126277 |
2018 |
|
Giant Cell Arteritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
[18F]FDG positron emission tomography in patients presenting with suspicion of giant cell arteritis-lessons from a vasculitis clinic.
|
29126277 |
2018 |
|
Metastatic non-small cell lung cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
|
27600280 |
2017 |